Company registration number 15449695 (England and Wales)
MEDICO PHARMACEUTICALS LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
PAGES FOR FILING WITH REGISTRAR
MEDICO PHARMACEUTICALS LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 4
MEDICO PHARMACEUTICALS LIMITED
BALANCE SHEET
AS AT
31 JANUARY 2026
31 January 2026
- 1 -
2026
2025
Notes
£
£
£
£
Current assets
Debtors
3
4,503
1,355
Cash at bank and in hand
499
100
5,002
1,455
Creditors: amounts falling due within one year
4
(49,078)
(11,408)
Net current liabilities
(44,076)
(9,953)
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
(44,176)
(10,053)
Total equity
(44,076)
(9,953)
For the financial year ended 31 January 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true
The financial statements were approved and signed by the director and authorised for issue on 27 October 2026
Mr R Jolly
Director
Company registration number 15449695 (England and Wales)
MEDICO PHARMACEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 JANUARY 2026
- 2 -
1
Accounting policies
Company information
Medico Pharmaceuticals Limited is a private company limited by shares incorporated in England and Wales. The registered office is Unit 5, Winsor And Newton Building, Whitefriars Avenue, Harrow, England, HA3 5RN.
1.1
Basis of preparation
These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.
The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.
The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.
1.2
Going concern
Atruet the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the director continues to adopt the going concern basis of accounting in preparing the financial statements.
1.3
Turnover
Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discounts, settlement discounts and volume rebates.
When cash inflows are deferred and represent a financing arrangement, the fair value of the consideration is the present value of the future receipts. The difference between the fair value of the consideration and the nominal amount received is recognised as interest income.
Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.
1.4
Cash and cash equivalents
Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.
1.5
Employee benefits
The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.
The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.
Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.
MEDICO PHARMACEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
1
Accounting policies
(Continued)
- 3 -
1.6
Retirement benefits
Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.
2
Employees
The average monthly number of persons (including directors) employed by the company during the year was:
2026
2025
Number
Number
Total
2
1
3
Debtors
2026
2025
Amounts falling due within one year:
£
£
Trade debtors
1,200
Other debtors
4,503
155
4,503
1,355
4
Creditors: amounts falling due within one year
2026
2025
£
£
Trade creditors
5,766
5,100
Taxation and social security
5,868
Other creditors
37,444
6,308
49,078
11,408
5
Related party transactions
Transactions with related parties
During the year the company entered into the following transactions with related parties:
Management charges
2026
2025
£
£
Entities with control, joint control or significant influence over the company
-
1,000
2026
2025
Amounts due to related parties
£
£
MEDICO PHARMACEUTICALS LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 JANUARY 2026
5
Related party transactions
(Continued)
- 4 -
Entities under common control of shareholders and directors
13,628
6,308
The amount disclosed above is included within other creditors due within one year. The loan is unsecured, interest-free, and repayable on demand.
6
Directors' transactions
During the year, Mr R Jolly borrowed £4,340 from the company. This was the maximum amount of the loan outstanding at any point of the year. Interest on the loan was charged at the official rate. The loan was fully paid within 9 months.
Loans
% Rate
Opening balance
Amounts advanced
Interest charged
Closing balance
£
£
£
£
3.75
-
4,340
163
4,503
-
4,340
163
4,503